Which statement about nicotine prevalence is true?

Prepare for the Certified Addictions Registered Nurse (CARN) Advanced Practice Test. Utilize flashcards and multiple-choice questions, complete with hints and explanations. Boost your readiness for the exam!

Multiple Choice

Which statement about nicotine prevalence is true?

Explanation:
Understanding prevalence involves distinguishing how we measure use over time. A 12-month prevalence tells us who has used nicotine in the past year, while lifetime prevalence includes anyone who has ever used nicotine at any point in their life. Because someone who used nicotine in the past year obviously has used it at least once in their life, lifetime prevalence cannot be lower than the 12-month figure. The statement that the past-year prevalence is 20% fits with typical public-health estimates and sits correctly above any lower lifetime figure. It respects the natural order that past-year use is a subset of lifetime use. The other options either imply unusually high recent use (30%) or, if interpreted as a standalone lifetime figure (15%), would violate the expected relationship with any plausible past-year figure. Therefore, stating that 12-month prevalence is 20% is the most consistent and true statement.

Understanding prevalence involves distinguishing how we measure use over time. A 12-month prevalence tells us who has used nicotine in the past year, while lifetime prevalence includes anyone who has ever used nicotine at any point in their life. Because someone who used nicotine in the past year obviously has used it at least once in their life, lifetime prevalence cannot be lower than the 12-month figure.

The statement that the past-year prevalence is 20% fits with typical public-health estimates and sits correctly above any lower lifetime figure. It respects the natural order that past-year use is a subset of lifetime use. The other options either imply unusually high recent use (30%) or, if interpreted as a standalone lifetime figure (15%), would violate the expected relationship with any plausible past-year figure. Therefore, stating that 12-month prevalence is 20% is the most consistent and true statement.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy